Omipalisib
Grundinformationen
- CAS
1086062-66-9- Standard-SMILES
COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F- InChIKey
CGBJSGAELGCMKE-UHFFFAOYSA-N- Summenformel
- C25H17F2N5O3S
- Durchschnittliche Molmasse
- 505,5 g/mol
- Monoisotopische Masse
- 505,10201684
Überblick
Omipalisib is a member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors. It has a role as a radiosensitizing agent, an autophagy inducer, an anticoronaviral agent, an antifibrotic agent, an antineoplastic agent, an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor and a mTOR inhibitor. It is a member of pyridines, a member of quinolines, a sulfonamide, an aromatic ether, a member of pyridazines and a difluorobenzene.
Namen und Bezeichner
- Bevorzugter Name
- Omipalisib
- IUPAC
- 2,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)-3-pyridinyl]benzenesulfonamide
- Englischer Name
- GSK-2126458
- Summenformel
- C25H17F2N5O3S
- Molmasse
- 505.5
Namen und Synonyme
Omipalisib1086062-66-9GSK2126458GSK-2126458GSK 21264582,4-difluoro-N-(2-methoxy-5-(4-(pyridazin-4-yl)quinolin-6-yl)pyridin-3-yl)benzenesulfonamideGSK-212GSK2122,4-difluoro-N-[2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl]benzenesulfonamideomipalisibum1X8F5A3NA0CHEBI:95093
Weitere Namen anzeigen
CS-55GSK458HYR-582GSK-2126458-AGSK2126458, >=98%Omipalisib GSK458
DTXSID101486042,4-difluoro-N-(2-(methyloxy)-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)benzenesulfonamideBenzenesulfonamide, 2,4-difluoro-N-(2-methoxy-5-(4-(4-pyridazinyl)-6-quinolinyl)-3-pyridinyl)-2,4-difluoro-N-{2-methoxy-5-[4-(pyridazin-4-yl)quinolin-6-yl]pyridin-3-yl}benzenesulfonamide2,4-difluoro-N-(2-methoxy-5-(4-pyridazin-4-ylquinolin-6-yl)pyridin-3-yl)benzenesulfonamide2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamideBenzenesulfonamide, 2,4-difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]-RefChem:856774
Datenbank-Bezeichner
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 3,3
- Polarare Oberfläche (TPSA)
- 115 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 10
- Frei drehbare Bindungen
- 6
- Schwere Atome
- 36
- Formalladung
- 0
- Komplexität
- 833
Experimentelle und physikochemische Eigenschaften
DrugsPharmaceuticals -> Listed in ZINC15
LogP3.09
Physikochemische Eigenschaften
- Schmelzpunkt
- 187 · 187-189℃
- Siedepunkt
- 715.6 · 715.6±70.0 °C(Predicted)
- Dichte
- 1.45 · 1.45
- storage temp.
- Refrigerator
- Löslichkeit
- Chloroform (Slightly), DMSO (Slightly), Methanol (Very Slightly, Heated)
- Aggregatzustand
- Solid
- pka
- 6.23 · 6.23±0.40(Predicted)
- Farbe
- White to Pale Yellow
- InChI
- InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3
- InChIKey
- CGBJSGAELGCMKE-UHFFFAOYSA-N
- SMILES
- C1(S(NC2=CC(C3=CC=C4C(=C3)C(C3=CC=NN=C3)=CC=N4)=CN=C2OC)(=O)=O)=CC=C(F)C=C1F
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Danger
H301 (50%): Toxic if swallowed [Danger Acute toxicity, oral]
P203, P260, P264, P270, P280, P301+P316, P301+P317, P318, P319, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Hazard Classes and CategoriesAcute Tox. 3 (50%)
Sicherheitsdaten
- wgk
- WGK 3
- hs_code
- 29350090
- Speicherklasse
- 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
- Hazard Classifications
- Acute Tox. 4 OralRepr. 2STOT RE 1
Chemie und Industrie
Anwendungen
BeschreibungGSK2126458 is a potent inhibitor of phosphoinositide 3-kinase isoforms (Kis = 19, 130, 24, and 60 pM for p110α, β, δ, and γ, respectively). It also inhibits mTOR in both mTORC1 and mTORC2 (Kis = 180 and 300 nM, respectively), as well as several common mutant forms of p110α. GSK2126458 is orally bioavailable, displays favorable pharmacokinetics, and shows efficacy in tumor growth models. GSK2126458 positively combines with inhibitors of discoidin domain receptor 1 (DDR1) inhibitor DDR1-IN-1 to suppress the growth of SNU-1040 colorectal cancer cells.
VerwendenA highly potent inhibitor of PI3K and the mammalian target of Rapamycin.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Zugehörige Reaktionen
5
Notizen zur Verbindung
Wird geladen…